For anyone weighing options in the United States, a driver is mandatory, and across six sessions in three weeks that means arranging somebody else's time repeatedly rather than once. The infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation. Programmes differ enormously in how seriously they take the therapeutic work around the infusion, ranging from employed therapists to a photocopied worksheet. Nothing about the United States changes that. The reason vital signs are tracked throughout is unglamorous: ketamine raises blood pressure and heart rate transiently, and someone needs to be watching when it does. It is worth carrying that into every conversation with a the United States provider.
Telehealth has a legitimate role here for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. It is the first thing to establish about any the United States programme. The useful framing is that comparing programmes in the United States is difficult because the variables that decide quality are rarely the ones displayed on a homepage. Travel time belongs in the treatment plan rather than being treated as a detail to solve later. Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. Patients researching the United States providers run into this constantly. That holds in the United States as it does everywhere: randomised controlled trials have reported rapid reductions in depressive symptom scores after subanaesthetic infusions, often visible within hours to days rather than the weeks conventional antidepressants require.
It is worth pausing on the underlying medicine before returning to the United States. Side effects during a session are common, usually transient, and worth knowing about in advance rather than discovering in the chair. Dissociation is the one people ask about most: a sense of distance from the body, altered perception of time, sometimes visual distortion. For most people it peaks partway through the infusion and resolves within twenty to thirty minutes of the drip finishing. Nausea is frequent enough that many clinics give an antiemetic pre-emptively. Blood pressure and heart rate typically rise modestly during administration, which is the reason continuous monitoring is standard and the reason uncontrolled hypertension is treated as a serious caution. Headache, dizziness and a period of grogginess afterwards are ordinary. Driving is prohibited for the rest of the day without exception.
How to decide without guessing
Appointment timing decides whether a course is compatible with employment, which is why the availability of early or late slots is more consequential than it sounds. Knowing in advance that the dissociative period is temporary, expected and monitored tends to make it considerably less frightening than encountering it unprepared. Preparation before the first session matters for the same reason: people who know in advance what the dissociative period feels like generally find it far less alarming. Resuscitation equipment on site and a clinician credentialed to manage sedation are the structural elements that make the treatment defensible outside a research setting.
It is worth pausing on the underlying medicine before returning to the United States. The mechanism is where ketamine departs from the antidepressants most people have already tried. Conventional selective serotonin reuptake inhibitors work primarily on monoamine systems and typically need four to six weeks before any effect is assessable. Ketamine acts on the glutamate system, principally as an antagonist at the N-methyl-D-aspartate receptor, and the downstream cascade it appears to trigger involves a surge in brain-derived neurotrophic factor and a measurable increase in synaptic connections in regions associated with mood regulation. Researchers describe this as a window of heightened neuroplasticity. The clinically useful framing is that ketamine may open a period during which the brain is more amenable to change, which is precisely why the therapeutic work done around the infusion matters as much as the infusion.
Anyone comparing the United States programmes will find this decisive: commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable and worth asking about specifically. Researchers describe the result as a window of heightened neuroplasticity, which is a hypothesis with support rather than a settled account. Read against the United States market, transient elevation in blood pressure and heart rate is expected, which is the reason monitoring runs continuously rather than at intervals. Uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step. Esketamine, sold as Spravato, holds FDA approval for treatment-resistant depression in adults alongside an oral antidepressant, which puts it in a different regulatory category from generic infusions.
Common misunderstandings worth clearing up
Nausea is common enough that many programmes give an antiemetic pre-emptively rather than waiting to see. Pairing sessions with structured psychological support follows directly from the mechanism, which makes its absence a substantive gap rather than a stylistic one. Monitoring during administration is not a formality, and the difference between continuous and intermittent observation is a reasonable thing to ask about directly. Each session occupies roughly two hours on site once administration, monitoring and recovery are counted, which is longer than most people budget for. That is as true in the United States as anywhere else in the country.
It is worth pausing on the underlying medicine before returning to the United States. Screening is where a careful programme distinguishes itself, and it happens before anyone discusses scheduling. A thorough intake covers cardiovascular history, because of the blood pressure response; personal and family history of psychosis or bipolar disorder, because of the risk of precipitating an episode; hepatic function, because the liver metabolises the drug; substance use history; current medications and their interactions; and pregnancy status. It should also establish what has already been tried and at what dose, since the term treatment-resistant carries a specific meaning that only applies after adequate trials of at least two antidepressants. A consultation that skips most of this and moves quickly to a package price is telling you something about how the clinic is run.
Ketamine is a Schedule III controlled substance, which formally recognises a potential for misuse and shapes how responsible programmes are structured. A separate line of research has examined rapid reduction in suicidal ideation specifically, which is a distinct question from sustained treatment of depression. A consultation that moves quickly from hello to a package price has skipped the assessment that determines whether treatment is appropriate at all. Asking for an annualised cost rather than a per-session figure produces a far more useful number and occasionally a revealing pause.
Cost, coverage and the numbers nobody posts
Asking whether integration support is included, who provides it and whether it costs extra separates two quite different models of care within a single phone call. In the United States the same rule applies: a programme should be able to say plainly who is in the building during a session, what their credential is, and what the plan is if a person becomes acutely distressed. Solid food is usually restricted for several hours beforehand, largely to limit nausea during administration. Dissociation is the effect people ask about most: a sense of distance from the body, altered time perception and sometimes visual distortion, typically peaking partway through and resolving within half an hour of the infusion ending. The United States listings on this page are organised so that this is checkable rather than assumed.
It is worth pausing on the underlying medicine before returning to the United States. Ketamine has been in continuous clinical use since the United States Food and Drug Administration approved it as a general anaesthetic in 1970, which makes it one of the better characterised drugs in modern medicine from a safety standpoint. What is new is not the molecule but the dose and the intention behind it. Anaesthetic dosing renders a person unconscious for surgery; the subanaesthetic dosing used in mood work is a fraction of that, typically calculated at around 0.5 milligrams per kilogram of body weight delivered slowly over roughly forty minutes. At that level the person stays awake, breathing on their own, able to speak and to signal discomfort. The half century of anaesthetic safety data is genuinely reassuring about the drug itself, and it is also not the same thing as long-term safety data for repeated low-dose psychiatric use, which is a younger and thinner body of evidence.
Applied to the United States, the point is this: dosing for mood indications sits far below anaesthetic levels, typically calculated near 0.5 milligrams per kilogram of body weight and delivered slowly across about forty minutes. Anyone searching for treatment in the United States meets the same wall of interchangeable clinic websites, all promising personalised care and none explaining what that means operationally. In 2023 the FDA warned publicly about compounded ketamine used at home without monitoring, citing sedation, dissociation and airway risk with no clinician present. That is as true in the United States as anywhere else in the country. Where the evidence is strongest concerns short courses in adults who have not responded to at least two adequate antidepressant trials. It is the first thing to establish about any the United States programme. A history of psychosis or a bipolar diagnosis changes the risk calculation substantially, which is why a thorough intake asks about family psychiatric history and not only personal history. An anaesthesiologist and a psychiatrist offering the same infusion are often running quite different programmes around it. Patients researching the United States providers run into this constantly.
Risks, contraindications and honest caution
Anyone comparing the United States programmes will find this decisive: continuous monitoring of blood pressure, heart rate and oxygen saturation is the baseline, because subanaesthetic dosing reliably produces a modest rise in the first two. The logistics of an induction course are what quietly determine whether people finish treatment or abandon it partway through. For anyone weighing options in the United States, headache, dizziness and several hours of grogginess afterwards are ordinary, and driving is prohibited for the remainder of the day without exception. The clinics that treat this as a psychiatric treatment rather than a procedure tend to build psychological support into the protocol rather than offering it as an upsell.
The United States comparison only becomes useful once this is clear. A standard induction course in most American clinics runs to six sessions delivered over two to three weeks, though the number is a convention inherited from early trial protocols rather than a figure settled by comparative research. Some people are offered four; some programmes run to eight. What happens after induction is the genuinely unresolved part of the field. Response, where it occurs, is often not permanent, and many patients move onto a maintenance schedule of a single session every two to six weeks. Any clinic that presents six infusions as a complete and finished course without discussing what maintenance might look like, and what it might cost over a year, is describing half the treatment.
Any programme presenting six sessions as a complete and finished treatment, without discussing maintenance, has described half of what is involved. It is worth carrying that into every conversation with a the United States provider. In the United States the same rule applies: someone who has not yet tried a first-line treatment is usually better served starting there, where the evidence is stronger, the cost lower and the risk profile better understood. A dose calculated against body weight and adjusted across a course reflects a different philosophy from one held constant regardless of what the previous session produced. The honest summary is that the short-term findings are encouraging and the long-term picture remains genuinely unsettled.
The practical checklist, written as prose
That holds in the United States as it does everywhere: solid food is usually restricted for several hours beforehand, largely to limit nausea during administration. Dissociation is the effect people ask about most: a sense of distance from the body, altered time perception and sometimes visual distortion, typically peaking partway through and resolving within half an hour of the infusion ending. Nothing about the United States changes that. Read against the United States market, integration, the structured work of making sense of a session afterwards, is the element most often missing from purely procedural clinics. The trial protocols that produced the evidence base were run in monitored medical environments, and the monitoring was part of what made them safe rather than an accessory to it. The United States listings on this page are organised so that this is checkable rather than assumed.
Before comparing anything specific to the United States, the underlying clinical picture is worth stating properly. Esketamine, marketed as Spravato, occupies a different regulatory position that is routinely blurred in advertising. It is the S-enantiomer of ketamine, delivered as a nasal spray, and the FDA approved it in 2019 for treatment-resistant depression in adults used alongside an oral antidepressant, then in 2020 for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour. Because it carries a Risk Evaluation and Mitigation Strategy, it can only be given at certified treatment centres, the patient must be observed for at least two hours afterwards, and they cannot drive until the following day. That is the entire practical difference for most people: esketamine is approved, insurable more often than not, and inconvenient; generic intravenous ketamine is off-label, usually paid out of pocket, and more flexible in how it is dosed.
Applied to the United States, the point is this: what happens financially if treatment is stopped partway through is a question best asked before the first session rather than after the third. Pairing sessions with structured psychological support follows directly from the mechanism, which makes its absence a substantive gap rather than a stylistic one. Transient elevation in blood pressure and heart rate is expected, which is the reason monitoring runs continuously rather than at intervals. The United States listings on this page are organised so that this is checkable rather than assumed. Weight-based dosing in the region of 0.5 milligrams per kilogram over roughly forty minutes is the convention, though clinics vary in whether they adjust it between sessions. A programme should be able to say plainly who is in the building during a session, what their credential is, and what the plan is if a person becomes acutely distressed. In the United States the same rule applies: the mechanism matters practically because it implies the days after a session may be unusually receptive to therapeutic work.
What to take from all of this
The gap between anaesthetic and psychiatric dosing is large enough that describing them as the same treatment obscures more than it explains. It is the first thing to establish about any the United States programme. Read against the United States market, legitimate programmes respond to the abuse potential with structure rather than reassurance: observed administration, no take-home injectable supply and defined session intervals. That holds in the United States as it does everywhere: coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment. Acting on a different receptor system explains both the speed of onset and why the treatment sometimes helps people whom other antidepressants have not. Reduced to essentials, search results for ketamine treatment in the United States return a remarkably uniform set of pages, which makes genuine comparison harder rather than easier.
Treatment decisions of this kind belong to a person and the clinician who knows their history. What a directory can usefully do is make sure nobody walks into that discussion missing something they needed.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.